February 2021 – Press release
Pre Diagnostics successfully completes proof of concept study for its PreADx immunoassay for detection of Alzheimer’s Disease
Pre Diagnostics announces that its PreADx immunoassay for early detection of Alzheimer’s Disease has successfully completed a clinical evaluation. The company now plans to further optimize the assay in advance of CE marking in Q2, 2021. The company’s focus on innate immunity paves the way for precision medicine approaches to AD.